Investment analysts at Maxim Group assumed coverage on shares of Femasys (NASDAQ:FEMY – Get Rating) in a research report issued on Friday, Stock Target Advisor reports. The firm set a “buy” rating and a $5.00 price target on the stock. Maxim Group’s target price would suggest a potential upside of 284.62% from the stock’s previous close.
Several other research firms have also recently commented on FEMY. HC Wainwright assumed coverage on shares of Femasys in a research report on Thursday, March 24th. They issued a “buy” rating and a $8.00 target price for the company. Chardan Capital lowered their price target on shares of Femasys from $25.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, March 25th.
Shares of FEMY remained flat at $$1.30 during mid-day trading on Friday. The stock had a trading volume of 13,163 shares, compared to its average volume of 25,939. The stock has a market cap of $15.35 million and a price-to-earnings ratio of -1.26. The business has a 50-day simple moving average of $1.59 and a 200-day simple moving average of $2.59. Femasys has a 52-week low of $1.26 and a 52-week high of $13.75.
A number of large investors have recently added to or reduced their stakes in the business. Clear Creek Financial Management LLC grew its stake in shares of Femasys by 190.2% in the fourth quarter. Clear Creek Financial Management LLC now owns 68,276 shares of the company’s stock worth $266,000 after acquiring an additional 44,752 shares during the period. BlackRock Inc. bought a new stake in shares of Femasys in the third quarter worth approximately $40,000. Baird Financial Group Inc. bought a new stake in Femasys during the fourth quarter valued at approximately $57,000. Oppenheimer & Co. Inc. bought a new stake in Femasys during the fourth quarter valued at approximately $514,000. Finally, CM Management LLC grew its position in Femasys by 66.7% during the fourth quarter. CM Management LLC now owns 100,000 shares of the company’s stock valued at $390,000 after buying an additional 40,000 shares during the period. Institutional investors and hedge funds own 4.54% of the company’s stock.
Femasys Company Profile (Get Rating)
Femasys Inc, a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
- Get a free copy of the StockNews.com research report on Femasys (FEMY)
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- Dividend Stocks and Your Roth IRA
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.